|
|
 |
|
Viewing report
|
|
|
|
Drug Delivery Technology - Revolutionizing CNS Therapies
PharmaVision, Dec 2007, Pages: 100
“The World Health Organization has indicated that CNS disorders are the major medical challenge of the 21st Century, yet treatments for most CNS disorders are either inadequate or absent. The CNS is the most challenging frontier for drug discovery largely because of the complexity of the brain and the existence of the BBB”
Alan Palmer, Chief Executive of Pharmidex, UK
The revenue derived from Central Nervous System (CNS) drugs is vast, in that such a large number of diseases and disease processes are grouped under the CNS “umbrella”. These include acute organic conditions, such as infection, pain (both acute and chronic); chronic organic conditions such as neoplasms, seizure disorders; chronic degenerative disorders such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and other dementias, as well as the range of functional disorders classified as mental illnesses: schizophrenia, affective and anxiety spectrum disorders, attention deficit hyperactivity disorder (ADHD), sleep disorders and addictions.
The CNS has always posed problems in terms of drug delivery, drug efficacy and safety/ tolerability because of the presence of the blood brain barrier (BBB). The BBB is composed of a layer of extremely tightly packed epithelial cells, saturated with enzymes designed to protect the brain by disallowing the entry of noxious substances via the bloodstream. The unfortunate by-product of this has been the problem of delivering beneficial drugs to the CNS in sufficient quantities to effectively treat the targeted condition without causing unacceptable systemic adverse reactions.
Administering drugs directly into the CNS e.g. intrathecally or intracerebrally, is an effective method of delivery but carries significant risks in terms of infection as well as being invasive
and unpleasant for the patient. In recent years, methods of by-passing the BBB have been proposed, trialed and are now available, such as osmotic permeability, the use of nanoparticles small enough to penetrate the BBB, ultrasonic adjunctive drug treatment, and stem-cell and gene therapy, which effectively provide a “self-cure” by promoting neuroplasticity and cell regeneration within the central nervous system itself.
Newer delivery methods such as transdermal drug delivery which can employ nanotechnology to increase absorption and bioavailability, as well as being non-invasive and simple to use are on the rise, and seem set to be used for a wide range of CNS disorders, including psychoses, pain and neurodegenerative disorders.
Use the incisive analysis, commentary, opinions and forecasts provided in this note to:
-gain an in-depth understanding of the technology landscape for invasive, minimally invasive and non-invasive delivery of CNS therapeutics and regenerative therapies
-assess the options available for the invasive delivery of small molecules, peptides, proteins, gene therapies and stem cells now & in the future
-assess the potential delivery options available for emerging non-invasive formulations including transdermal, intranasal, oral and buccal melts
-evaluate the use of ultrasound and convection enhanced delivery as alternative methods for CNS delivery
-gauge the current & future technology requirements of pharma, biotech & medical device companies developing CNS products & devices
-analyze how the market is evolving & the influence that drug delivery may have on pharma CNS pipelines
-identify key pharma & delivery companies focusing on the improved delivery of existing & novel CNS agents
Seven Questions this Note Answers:
1. How will the drug delivery technology drivers change in the CNS arena during the next decade and beyond?
2. What are the key delivery technologies and devices in the CNS field?
3. When are products and medical devices which utilize these key delivery technologies likely to reach the market?
4. Which drug delivery technologies are likely to win in the near-term and the long-term, and why?
5. Which companies are the winners in each technology category?
6. How are drug delivery technologies evolving to meet the demands of the CNS market?
7. Where are the market opportunities now and in the future?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Drug Delivery in Cancer - Technologies, Markets and Companies
Transdermal Drug Delivery - Technologies, Markets, and Companies
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Nanoparticle Drug Delivery Market Report
Innovation in Drug Delivery: The Future of Nanotechnology and Non-invasive Protein Delivery
Drug Delivery: Active Transdermal Delivery Systems
Active Transdermal Delivery
CNS Therapeutics - Global Strategic Business Report
Drug Delivery Technology - Revolutionizing Cancer Therapies
Intranasal Drug Delivery - US Market Trends & Analysis
Intranasal Drug Delivery - US Market Trends & Analysis
|
|
|
|
